Contact Us

Aricept
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Aricept


AddThis Social Bookmark Button

Aricept Side Effects May Be Linked To Heart Disease Lawsuits

Aricept | Lawsuits, Lawyers |Side Effect: Heart Disease, Death, Heart Problems

The FDA has begun examining the results of a study of the drug Aricept, which is used to treat Alzheimer's disease. The study examined 974 patients suffering from dementia. There were 11 deaths among patients taking Aricept as compared to no deaths occurred among those taking the placebo. The study was carried out by Eisai, a Japanese pharmaceutical company that sells Aricept. Aricept is also sold by Pfizer. Susan Bro, a spokeswoman for the FDA, said the agency is examining the results of the study. The agency undertook a review of earlier Aricept studies and found no cause for concern. Medical experts say that the new study should not be written off and that it might indicate that Aricept and similar drugs increase the risks of heart disease, The New York Times reported. An Eisai spokesperson said Aricept is safe and the company is not recommending any changes to the drug's label.

More Research Needed on Aricept and Heart Problems

Last year, a British study concluded that Aricept does not delay the onset of disability or the need for nursing-home care for Alzheimer's patients. The study said the drug provided little overall benefit and was expensive. Dr. Lon Schneider, a professor of psychiatry, neurology and gerontology at the University of Southern California, believes that while no additional large trials of Aricept have found a similar risk, it does not indicate that such a risk is absent. Few trials have followed patients for long enough or included enough patients with serious heart problems.

Legal Help for Aricept Victims

If you or a family member were adversely affected by Aricept, contact Parker & Waichman, LLP for a free case evaluation with a defective drug side effects lawyer. Please fill out the form at the right or call 1-800-LAW-INFO (1-800-529-4636) today.

AriceptRSS Feed

FDA Sued for Allowing High-Dose Aricept to Remain on Market

Sep 6, 2012 | Parker Waichman LLP
A public health advocate is suing the Food and Drug Administration (FDA) over a case of what it calls “foot dragging” because the agency will not ban the highest dose of the Alzheimer’s disease drug Aricept. Public Citizen filed a lawsuit against the FDA this week, saying that the agency has not responded to a petition filed by the group to outlaw the highest dose of the popular drug that’s designed to control symptoms of the debilitating disease that affects millions...
FDA Sued for Allowing High-Dose Aricept to Remain on Market »

Petition Asks FDA to Pull Aricept High Dose Version from the Market

May 19, 2011 | Parker Waichman LLP
A leading consumer advocacy group says the highest dose of the Alzheimer's treatment Aricept (donepezil) is dangerous and ineffective, and should be removed from the market.   Public Citizen has filed a petition with the U.S. Food & Drug Administration (FDA) asking that the 23-milligram (mg) dose version of Aricept be pulled from the market immediately.  A prominent geriatrician from Johns Hopkins University School of Medicine has joined Public Citizen in advocating for the...
Petition Asks FDA to Pull Aricept High Dose Version from the Market »

Dementia Drugs May be Risky

May 28, 2009 | Parker Waichman LLP
We have long been writing about the serious side effects associated with some popular dementia drugs. Now, ScienceDaily is reporting that these adverse effects could be placing the elderly at risk, citing Sudeep Gill, a geriatrics professor at Queen’s University who is also an Ontario Ministry of Health and Long-term Care Career Scientist working at Providence Care's St. Mary's of the Lake Hospital in Kingston.Aricept, Exelon, and Reminyl are in a class of drugs called cholinesterase...
Dementia Drugs May be Risky »

Aricept, Zantac, Detrol, other Anticholinergic Drugs Lined to Mental Impairment in Elderly

May 6, 2008 | Parker Waichman LLP
Two separate reports written by researchers at Wake Forest University School of Medicine support findings released recently concerning anticholinergic medications like Aricept, Zantac and Detrol.  The studies found that anticholinergic drugs may be adversely affecting the thinking skills of older patients, a phenomenon not observed in those patients studied who do not take these medications.  The studies also indicate that anticholinergics may cause older patients to experience a...
Aricept, Zantac, Detrol, other Anticholinergic Drugs Lined to Mental Impairment in Elderly »

Eleven Deaths during ARICEPT Trial Raises Concern over FDA Application to Permit Wider Use of the Drug

Mar 20, 2006 | Newsinferno News Staff
An article in the October, 2005, issue of Worst Pills Best Pills Newsletter from the consumer watchdog group, Public Citizen, reported that three Alzheimer’s drugs had been found to be of “questionable “ value in a study published in the British Medical Journal (BMJ) (August 5, 2005). Those drugs were donepezil (ARICEPT), rivastigmine (EXELON), and galantamine (REMINYL). The conclusion reached by Public Citizen was that the study “adds additional evidence to support our...
Eleven Deaths during ARICEPT Trial Raises Concern over FDA Application to Permit Wider Use of the Drug »

More Aricept News

Law Dragon Best Lawyers Peer Review Rated Avvo Protected by Copyscape Web Copyright Protection Software php-5